Quantcast

Latest Targeted therapy Stories

2014-07-02 16:24:20

ROCKVILLE, Md., July 2, 2014 /PRNewswire/ -- A collaborative study between OncoPlex Diagnostics, Vall d´Hebron Institute of Oncology (VHIO), and Memorial Sloan Kettering Cancer Center, with

2014-06-26 23:01:59

Researchers at UC Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs

2014-06-26 12:27:15

LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

2014-06-26 08:27:43

- Trial will measure investigational compound's efficacy and safety in patients with HER2-negative breast cancer, associated with BRCA 1, BRCA 2 mutations NORTH CHICAGO, Ill.,

2014-06-16 16:25:14

Lung-MAP Trial Will Test Five Investigational Approaches, Including Amgen's Rilotumumab, an Investigational Fully Human Monoclonal Antibody THOUSAND OAKS, Calif., June 16, 2014 /PRNewswire/

2014-06-09 12:26:41

Public Healthcare Systems in Brazil and Mexico Cover Targeted Therapies but with Indication-Specific Restrictions, According to Findings from Decision Resources Group BURLINGTON, Mass., June

2014-06-03 11:48:40

At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs).

2014-06-03 11:22:42

A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).

2014-06-03 08:31:30

Pathway Analysis Confirms the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, June 3, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused

2014-06-02 12:29:47

Six Phase 3 / Pivotal Trials with Array's MEK Inhibitors Advancing BOULDER, Colo., June 2, 2014 /PRNewswire/ -- Two Array BioPharma-invented MEK inhibitors, binimetinib (MEK162) and


Word of the Day
deuteragonist
  • A person in a secondary role, specifically the second most important character (after the protagonist).
The word 'deuteragonist' comes from a Greek word meaning 'an actor of second-class parts'.
Related